My recent coverage of UroGen Pharma (NASDAQ: URGN ) was the prospective risk-taker's manifesto on a very shaky FDA decision. Now that this thesis has worked out, the "predictions" laid out in that article appear to be nearlyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the p ...